Pharma News

Asprius Lifesciences has announced that it has developed treatment for Diabetic Neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination that holds promise in treating peripheral neuropathy.

CDSCO has taken serious action against companies which were alerted by WHO for suspicious activities and involved in production of hazardous products in the market.

WHO has issued alerts in three cases of syrup products exported from India. Subsequent to the reports, Central Drugs Standard Control Organization (CDSCO) in coordination with State Drug Controllers carried out joint investigations.

The Indian government has taken a dominant step towards treatment of patients suffering from rare diseases. So far in this fiscal year, the government has allocated Rs. 92.84 crore for treatment of rare diseases.

As per the data available with Indian Council of Medical Research (ICMR), 9,675 patients have been enrolled since November, 2019 on the portal of National Registry for Rare and Other Inherited Disorders (NRROID) out of which 4,408 patients are from centrally governed Hospitals.

Mirum Pharmaceuticals, Inc announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).

The European Commission (EC) approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced today.

AstraZeneca Pharma India Limited has received Permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.

Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults. Forxiga (dapagliflozin) was developed by Bristol-Myers Squibb and AstraZeneca. It belongs to a class of drugs known as SGLT2 (sodium-glucose cotransporter 2) inhibitors.

The World Health Organization (WHO) is sharing its latest guidance on sexually transmitted infections (STI) at the STI & HIV 2023 World Congress taking place in Chicago, the United States of America, on 24-27 July 2023. With STIs on the rise, WHO is calling for better access to testing and diagnostic services. At the congress, WHO will also discuss its latest STI research agenda and antimicrobial resistance (AMR) in gonorrhoea.

Orexo AB announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc have appealed the patent litigation decision issued by the US District Court for the District of New Jersey relating to Orexo’s patents protecting ZUBSOLV  (buprenorphine and naloxone) sublingual tablets (CIII) in the US.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.